Literature DB >> 24575502

On-spot rheumatology consultations in a multilevel geriatric hospital.

Emily Lubart1, Arthur Leibovitz2, Vadim Shapir2, Refael Segal2.   

Abstract

BACKGROUND: Musculoskeletal and joint disorders are extremely common in the elderly. They directly affect mobility, gait stability, quality of life, and independence.
OBJECTIVES: To assess the nature of joint problems encountered in a geriatric inpatient population and evaluate the contribution of a rheumatologist.
METHODS: We reviewed the rheumatology consultation records that were conducted in a geriatric medical center over a 10 year period.
RESULTS: A total of 474 consultations were held; most of these patients (86%) were hospitalized in the acute geriatric departments, 10% in the rehabilitation ward and 4% in the long-term care wards. Some patients were seen more than once. A rheumatologic joint problem was the main reason for hospitalization in 53% of these patients. Monoarthritis was the most frequent complaint (50%), followed by pauciarticular arthritis (two to five joints) in 30% of patients. Arthrocentesis, diagnostic and therapeutic, was performed in 225 patients, most of them in knee joints (81%). The most frequent diagnosis was osteoarthritis with acute exacerbation (28%), followed by gout (18%), pseudo-gout (9%) and rheumatoid arthritis (9%). In 86 cases (18%) the diagnosis was a non-specific rheumatologic problem: arthralgia, nonspecific generalized pain, or fibromyalgia.
CONCLUSIONS: Prompt and appropriate evaluation, as well as arthrocentesis and treatment initiation, including local injections, were made possible by the presence of an in-house rheumatologist.

Entities:  

Mesh:

Year:  2014        PMID: 24575502

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  1 in total

1.  An investigation of the independent risk factors that differentiate gout from pseudogout in patients with crystal-induced acute arthritis: a cross-sectional study.

Authors:  Chayawee Muangchan; Thitirat Bhurihirun
Journal:  Rheumatol Int       Date:  2017-12-06       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.